TAO kinase 1 | TAO subfamily | IUPHAR/BPS Guide to PHARMACOLOGY

Top ▲

TAO kinase 1

target has curated data in GtoImmuPdb

Target id: 2233

Nomenclature: TAO kinase 1

Abbreviated Name: TAO1

Family: TAO subfamily

Annotation status:  image of an orange circle Annotated and awaiting review. Please contact us if you can help with reviewing.  » Email us

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 1001 17q11.2 TAOK1 TAO kinase 1
Mouse - 1001 11 B5 Taok1 TAO kinase 1
Rat - 1001 10 q26 Taok1 TAO kinase 1
Previous and Unofficial Names
MAP3K16 | MARKK | prostate-derived sterile 20 (Ste20)-like kinase 2 | PSK2 | thousand and one amino acid protein 1 | thousand and one kinase 1
Database Links
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
RefSeq Nucleotide
RefSeq Protein
Enzyme Reaction
EC Number:

Download all structure-activity data for this target as a CSV file

Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
compound 18 [PMID: 20873740] Hs Inhibition 6.4 pIC50 5
pIC50 6.4 (IC50 4.2x10-7 M) [5]
DiscoveRx KINOMEscan® screen
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform.
Reference: 2,7

Key to terms and symbols Click column headers to sort
Target used in screen: TAOK1
Ligand Sp. Type Action Value Parameter
staurosporine Hs Inhibitor Inhibition 9.4 pKd
NVP-TAE684 Hs Inhibitor Inhibition 7.6 pKd
AST-487 Hs Inhibitor Inhibition 7.5 pKd
lestaurtinib Hs Inhibitor Inhibition 7.2 pKd
AT-7519 Hs Inhibitor Inhibition 6.9 pKd
PP-242 Hs Inhibitor Inhibition 6.9 pKd
alvocidib Hs Inhibitor Inhibition 6.8 pKd
pazopanib Hs Inhibitor Inhibition 6.6 pKd
tozasertib Hs Inhibitor Inhibition 6.5 pKd
linifanib Hs Inhibitor Inhibition 6.5 pKd
Displaying the top 10 most potent ligands  View all ligands in screen »
EMD Millipore KinaseProfilerTM screen/Reaction Biology Kinase HotspotSM screen
A screen profiling 158 kinase inhibitors (Calbiochem Protein Kinase Inhibitor Library I and II, catalogue numbers 539744 and 539745) for their inhibitory activity at 1µM and 10µM against 234 human recombinant kinases using the EMD Millipore KinaseProfilerTM service.

A screen profiling the inhibitory activity of 178 commercially available kinase inhibitors at 0.5µM against a panel of 300 recombinant protein kinases using the Reaction Biology Corporation Kinase HotspotSM platform.


Reference: 1,4

Key to terms and symbols Click column headers to sort
Target used in screen: TAO1/TAOK1
Ligand Sp. Type Action % Activity remaining at 0.5µM % Activity remaining at 1µM % Activity remaining at 10µM
staurosporine Hs Inhibitor Inhibition 0.9 0.0 0.5
Cdk1/2 inhibitor III Hs Inhibitor Inhibition 11.3 0.0 1.0
JNJ-7706621 Hs Inhibitor Inhibition 18.8 15.0 4.0
JAK3 inhibitor VI Hs Inhibitor Inhibition 22.6 8.0 2.0
K-252a Hs Inhibitor Inhibition 26.0 5.0 3.0
pazopanib Hs Inhibitor Inhibition 28.9
PKR inhibitor Hs Inhibitor Inhibition 37.5 11.0 0.0
SU11274 Hs Inhibitor Inhibition 41.9 34.0 8.0
Gö 6976 Hs Inhibitor Inhibition 43.9 7.0 10.0
tozasertib Hs Inhibitor Inhibition 44.6
Displaying the top 10 most potent ligands  View all ligands in screen »
Immunopharmacology Comments
TAOK1 has been discovered to function as a negative regulator of IL-17 (IL-17A)-mediated signal transduction and inflammation [8]. IL-17 is a proinflammatory cytokine involved in the development of several autoimmune diseases, including inflammatory bowel disease and Sjögren's syndrome. TAOK1 appears to interact with IL-17RA, and this action prevents IL-17RA-Act1-TRAF6 signaling complex formation, and inhibits NF-κB and MAP kinase pathway activation. This in turn leads to a reduction in the expression of IL-17-induced proinflammatory mediators (e.g. IL-6, CXCL1, CXCL2, CCL20 and CSF3). TAOK1 is revealed as a component of the regulatory system that controls IL-17activity that is necessary to limit harmful IL-17-driven inflammation and autoimmune disease. Decreased TAOK1 expression has been reported in the colons of ulcerative colitis patients. Thus, the accumulating evidence delineating TAOK1 's functions indicate that this kinase is involved in the pathogenesis of IL-17-related autoimmune conditions.
Physiological Consequences of Altering Gene Expression
Taok1-deficient mice are more sensitive to TNBS-induced inflammatory bowel disease (IBD) than wild-type mice.
Species:  Mouse
Technique:  Conditional knockout by crossing Taok1fl/fl mice with Pvillin-Cre transgenic mice to generate with Taok1 deletion specifically in intestinal epithelial cells.
References:  8
Overexpression of TAOK1 in HeLa cells downregulates IL-17-induced phosphorylation of NF-&kapp;B and MAPK kinases (i.e. TAOK1 inhibits the IL-17 signaling pathway).
Species:  Human
Tissue:  HeLa cells.
Technique:  Transient expression.
References:  8
General Comments
As well as being a member of the STE20-like kinases family, TAOK1 is also a member of the MAP kinase kinase kinase family, and is involved in MAPK signaling. It is reported to be involved in microtubule dynamics and mitotic progression [3], and the p38 and JNK response to DNA damage and stress stimuli [6].


Show »

1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1039-45. [PMID:22037377]

2. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1046-51. [PMID:22037378]

3. Draviam VM, Stegmeier F, Nalepa G, Sowa ME, Chen J, Liang A, Hannon GJ, Sorger PK, Harper JW, Elledge SJ. (2007) A functional genomic screen identifies a role for TAO1 kinase in spindle-checkpoint signalling. Nat. Cell Biol., 9 (5): 556-64. [PMID:17417629]

4. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem. J., 451 (2): 313-28. [PMID:23398362]

5. Menichincheri M, Albanese C, Alli C, Ballinari D, Bargiotti A, Caldarelli M, Ciavolella A, Cirla A, Colombo M, Colotta F et al.. (2010) Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J. Med. Chem., 53 (20): 7296-315. [PMID:20873740]

6. Raman M, Earnest S, Zhang K, Zhao Y, Cobb MH. (2007) TAO kinases mediate activation of p38 in response to DNA damage. EMBO J., 26 (8): 2005-14. [PMID:17396146]

7. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem. Biol., 17 (11): 1241-9. [PMID:21095574]

8. Zhang Z, Tang Z, Ma X, Sun K, Fan L, Fang J, Pan J, Wang X, An H, Zhou J. (2018) TAOK1 negatively regulates IL-17-mediated signaling and inflammation. Cell. Mol. Immunol., 15 (8): 794-802. [PMID:29400705]

How to cite this page

TAO subfamily: TAO kinase 1. Last modified on 12/02/2018. Accessed on 14/08/2020. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2233.